1至8批国家集采药品接续采购开标，医疗创新ETF(516820)红盘上扬

Group 1 - The core viewpoint of the news highlights the positive performance of the medical and healthcare innovation sector, with the China Securities Medical and Medical Device Innovation Index rising by 0.57% as of February 10, 2026, and several key stocks showing significant gains [1] - The recent round of national centralized procurement for medicines has resulted in proposed selections for 316 commonly used drugs, with participation from 5.1 million medical institutions and 1,091 domestic and foreign companies submitting 4,623 products for bidding [1] - The medical innovation ETF has also seen an increase of 0.55%, with the latest price reported at 0.37 yuan, indicating a growing interest in the sector [1] Group 2 - Donghai Securities notes the sustained high demand in the small nucleic acid sector, with an expanding market size and increased interest from multinational pharmaceutical companies, as well as recognition of domestic companies' technologies internationally [2] - Investment recommendations focus on three main areas: innovative biotech firms with core delivery technologies, industry leaders in chronic disease sectors with advanced pipelines, and key companies in the small nucleic acid supply chain benefiting from global commercialization [2] - The China Securities Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability and growth potential, with the top ten weighted stocks accounting for 63.9% of the index [2]